1.
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
by Zost, Seth J
Nature medicine, 2020, Vol.26 (9), p.1422-1427
2.
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
by Juno, Jennifer A
Nature medicine, 2020, Vol.26 (9), p.1428-1434
3.
Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications
by Sparrow, Erin
Vaccine, 2016, Vol.34 (45), p.5442-5448
4.
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
by Sofen, Howard, MD
Journal of allergy and clinical immunology, 2014, Vol.133 (4), p.1032-1040
5.
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies
by Leborgne, Christian
Nature Medicine, 2020, Vol.26 (7), p.1096-1101
6.
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
by Caskey, Marina
Nature medicine, 2017, Vol.23 (2), p.185-191
7.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals
by Bar-On, Yotam
Nature medicine, 2018, Vol.24 (11), p.1701-1707
8.
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo
by DiLillo, David J
Nature medicine, 2014, Vol.20 (2), p.143-151
9.
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection
by HRABER, Peter
AIDS (London), 2014, Vol.28 (2), p.163-169
10.
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
by Tostanoski, Lisa H
Nature medicine, 2020, Vol.26 (11), p.1694-1700
11.
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models
by Shan, Chao
Nature medicine, 2017, Vol.23 (6), p.763-767
12.
T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers
by Arunachalam, Prabhu S
Nature medicine, 2020, Vol.26 (6), p.932-940
13.
Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques
by Hessell, Ann J
Nature medicine, 2016, Vol.22 (4), p.362-368
14.
Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model
by Park, Jae-Keun
Nature medicine, 2020, Vol.26 (8), p.1240-1246
15.
The role of antibodies in HIV vaccines
by Mascola, John R
Annual review of immunology, 2010, Vol.28 (1), p.413-444
16.
Humoral signatures of protective and pathological SARS-CoV-2 infection in children
by Bartsch, Yannic C
Nature medicine, 2021, Vol.27 (3), p.454-462
17.
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape
by Moore, Penny L
Nature medicine, 2012, Vol.18 (11), p.1688-1692
18.
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
by van Schouwenburg, Pauline A
Annals of the rheumatic diseases, 2013, Vol.72 (1), p.104-109
19.
ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
by Alharbi, Naif Khalaf
Vaccine, 2017, Vol.35 (30), p.3780-3788
20.
Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man t...
by Ramsauer, Katrin, PhD
The Lancet infectious diseases, 2015, Vol.15 (5), p.519-527
